|
EP3344250A2
|
|
Quinoxalinyl-piperazinamide methods of use
|
|
CN107750160A
|
|
The purposes and preparation method of fluoro cyclopentenyl cytimidine
|
|
AU2015200291A1
|
|
Polymeric systems for the delivery of anticancer agents
|
|
MX2015017539A
|
|
Nanoparticulate compositions and formulations of piperazine compounds.
|
|
EP3378855A1
|
|
Process for the preparation of 4-amino-1-((1s,4r,5s)-2-fluoro-4,5-dihidroxy-3-hydroxy-methyl-cyclopent-2-enyl)-1h-pyrimidin-2-one
|
|
AU2014227992A1
|
|
Tetrahydroisoquinolin-2-yl-(quinazolin-4-yl) methanone compounds as cancer cell growth inhibitors
|
|
WO2013006808A2
|
|
Clavulanic acid for treatment of restless legs syndrome
|
|
MX2012004416A
|
|
Polymeric systems for the delivery of anticancer agents.
|
|
CN102413814A
|
|
Clavulanate formulation for neuroprotection and treatment of neurodegenerative disorders
|
|
AU2009302387A1
|
|
HPMA - docetaxel or gemcitabine conjugates and uses therefore
|
|
US2009270358A1
|
|
Pharmaceutical formulation of clavulanic acid
|
|
US2008182871A1
|
|
5, 6, or 7-substituted-3-(hetero)arylisoquinolinamine derivatives and therapeutic use thereof
|
|
AU2004207576A1
|
|
Antisense oligonucleotides that inhibit expression of HIF-1
|
